PDMR Notification RSU Vesting

PureTech Health PLC

31 July 2026

 

31 July 2026

PureTech Health plc

PDMR Notifications

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announces that awards of restricted share units ("RSUs") granted by PureTech on 19 November 2025 to certain non-executive directors ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested in full on 9 June 2026 the day immediately preceding the Company's Annual General Meeting of Stockholders. Each PDMR received vested ordinary shares on 29 July 2026.

The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMRs, 13,552,467 shares of which are held in treasury by the Company.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	John LaMattina Robert Langer Kiran Mazumdar-Shaw Sharon Barber-Lui Michele Holcomb
2	Reason for the notification
a)	Position/status	Non-Executive Directors
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	PureTech Health plc
b)	LEI	213800LVPDNO2Z9T9I39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74
b)	Nature of the transaction	Issuance of ordinary shares in settlement of certain vested RSUs under the PureTech Health Performance Share Plan.
c)	Price(s) and volume(s)	Recipient Price Amount John LaMattina 0.01 GBP 93,944 ordinary shares Robert Langer 0.01 GBP 93,944 ordinary shares Kiran Mazumdar-Shaw 0.01 GBP 93,944 ordinary shares Sharon Barber-Lui 0.01 GBP 93,944 ordinary shares Michele Holcomb 0.01 GBP 93,944 ordinary shares
d)	Aggregated information - Aggregated volume - Price	Price Aggregate Volume 0.01 GBP 469,720 ordinary shares
e)	Date of the transaction	29 July 2026
f)	Place of the transaction	London Stock Exchange (XLON)

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh. 

Contact:

PureTech

Investor Relations

[e-mail]

 

END